key: cord-0896449-aly2bv3m
authors: Million, Matthieu; Giraud-Gatineau, Audrey; Lagier, Jean-Christophe; Parola, Philippe; Gautret, Philippe; Raoult, Didier
title: Reply to Lebeaux D, Revest M. No evidence of clinical benefits of early treatment of COVID-19 patients with hydroxychloroquine and azithromycin
date: 2020-12-13
journal: Travel Med Infect Dis
DOI: 10.1016/j.tmaid.2020.101954
sha: f5a48e75d80ffec06f3157728e701c2cb1c1faf4
doc_id: 896449
cord_uid: aly2bv3m

nan

clinical benefits of early testing and treatment of COVID-19 patients with 17 hydroxychloroquine (HCQ) and azithromycin (AZ) reported in our study. 18 The authors of the commentary suggest that, due to our strategy of early and massive 19 non-selective screening, the good evolution (low mortality of 0.75%) was close to that 20 observed in the untreated general population and was influenced by the selection of young 21 healthy patients with mild infections. However, the strategy of massive and early screening is 

No evidence of clinical benefits of early treatment of COVID